

MEDICINES NOT REIMBURSED THROUGH NATIONAL PRICES AND DIRECTLY COMMISSIONED BY NHS ENGLAND



VERSION 11 PUBLISHED DECEMBER 2016

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TAPOLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
ABACAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
ABACAVIR + LAMIVUDINE + DOLUTEGRAVIR (TRUQUEO®)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/b/AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
ABACAVIR + LAMIVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
ABALOPARATIDE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ABATACEPT	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓		✓	
ABATACEPT	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA195, TA280)	NICE	NICE	NICE			✓	
ABIRATERONE	CANCER	NHS ENGLAND	HORMONE ANTAGONISTS	TA259, 387 (SEE ALSO SSC1438) ONLY IN ENZALUTAMIDE NAIVE PATIENTS	NICE/NHS ENGLAND POLICY	NICE	SACT	✓		✓	
ADALIMUMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓		✓	
ADALIMUMAB	UVEITIS - PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: D12X02	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓	✓		
ADALIMUMAB	UVEITIS - ADULTS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: D12/P/a)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ADALIMUMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA		✓		
ADALIMUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA130, TA143, TA146, TA187, TA199)	NICE	NICE	NICE AUDIT			✓	
ADALIMUMAB	HIDRADENITIS SUPPURATIVA	NHS ENGLAND	CYTOKINE MODULATORS	NICE TA 392	NICE	NICE	NICE AUDIT	✓	✓		
ADEFOVIR	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED (CG165)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
AFATINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA319	NICE	NICE	SACT			✓	
AFLIBERCEPT	CANCER	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED (TA307)	AS PER CDIFR APPROVAL	AS PER CDIFR APPROVAL	SACT			✓	
AGALSIDASE ALFA	FABRY'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
AGALSIDASE BETA	FABRY'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
ALBUTREPENONACOG ALFA	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK		✓		
ALBUTROPIN	ADULT ONSET GROWTH HORMONE DEFICIENCY	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ALDESLEUKIN	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT		✓		
ALEMTUZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TA312	NICE	NICE	NICE AUDIT	✓		✓	✓
ALEMTUZUMAB	PRE-TRANSPLANT IMMUNOSUPPRESSION	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TRUST GUIDELINES: ISLET TRANSPLANTATION (ONLY IF PROVIDED AT ZERO DRUG COST)	TRUST GUIDELINES	TRUST GUIDELINES			✓		
ALEMTUZUMAB	CLL	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	TRUST GUIDELINES: (ONLY IF PROVIDED AT ZERO DRUG COST)	TRUST GUIDELINES	TRUST GUIDELINES	SACT			✓	
ALEMTUZUMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY (ONLY IF PROVIDED AT ZERO DRUG COST)	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA		✓		
ALGLUCOSIDASE ALFA	POMPE DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
ALIPOGENE TIPARVOVEC	LIPOPROTEIN LIPASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ALISPORVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ALPHA-1 ANTITRYPSIN	ALPHA-1 ANTITRYPSIN DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ALPHA MANNOSIDASE RECOMBINANT HUMAN	ALPHA MANNOSIDASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
AMBRISENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY		✓		
AMIFAMPRIDINE PHOSPHATE	LEMS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16009/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
AMIKACIN INHALATION	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
AMIKACIN LIPOSOMAL	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
AMPHOTERICIN LIPOSOMAL	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			✓	
ANAKINRA	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓		✓	
ANAKINRA	SPECIALIST AUTOINFLAMMATORY DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ANAKINRA	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ANAKINRA	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
ANIDULAFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			√	
ANTIHAEMOPHILIC FACTOR/VON WILLEBRAND FACTOR COMPLEX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			√	
ANTILYMPHOCYTE GLOBULIN	APLASTIC ANAEMIA ORGAN TRANSPLANT	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES			√		
ANTIPSEUDOMONAS AERUGINOSA lyf	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ANTITHROMBIN III	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				√	
ANTITHYMOCYTE IMMUNOGLOBULIN	APLASTIC ANAEMIA ORGAN TRANSPLANT	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES			√		
APREMILAST	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ARAGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
ASFOTASE ALFA	HYPOPHOSPHATASIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ASUNAPREVIR + DACLATASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ATACICEPT	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ATALUREN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NICE HST3	NICE	NICE	NORTHSTAR DATABASE	√	√		
ATAZANAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
ATAZANAVIR + COBICICISTAT (EVOTAZ®)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
AVORALSTAT	HEREDITARY ANGIOEDEMA	NHS ENGLAND	ALLERGIC EMERGENCIES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
AXITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA333 (also refer to circular SSC1508)	NICE	NICE	SACT			√	
AZACITIDINE	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	TA218	NICE	NICE	SACT			√	
AZTREONAM LYSINE	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			√*	√*
AZTREONAM LYSINE	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16001/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BARICITINIB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
BASILIXIMAB	RENAL TRANSPLANT	NHS ENGLAND	CORTICOSTEROIDS AND OTHER IMMUNOSUPPRESSANTS	TA85 & TA99	NICE	NICE			√		
BECLABUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BEDAQUILINE	EXTENSIVELY DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
BEDAQUILINE	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
BEGELOMAB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	MALIGNANT DISEASE AND IMMUNOSUPPRESSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BELATACEPT	RENAL TRANSPLANT	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED - NICE TA IN PROGRESS	NICE TA IN PROGRESS	NICE TA IN PROGRESS	NICE TA IN PROGRESS			√	
BELIMUMAB	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NICE TA 397	NICE	NICE	NICE AUDIT	√		√	
BENRALIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BERACTANT	RESPIRATORY DISTRESS SYNDROME	NHS ENGLAND	PULMONARY SURFACTANTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				√	
BETAINE	HOMOCYSTINURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
BEVACIZUMAB	CANCER	CDF	ANTINEOPLASTIC DRUGS	CDF POLICY	CDF	CDF	SACT			√	
BEVACIZUMAB	NEUROFIBROMATOSIS	NHS ENGLAND	ANTINEOPLASTIC DRUGS	AS PER NATIONAL PROTOCOL (SEE NF2 SERVICE SPEC)	AS PER NATIONAL PROTOCOL	AS PER NATIONAL PROTOCOL	AS PER NATIONAL PROTOCOL		√		
BIMAGRUMAB	INCLUSION BODY MYOSITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BIOTIN	MULTIPLE SCLEROSIS	NHS ENGLAND	VITAMINS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BLISIBIMOD	SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BOCEPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA253	NICE	NICE	HEPATITIS C MDS	√		√	
BORTEZOMIB	ORGAN REJECTION POST KIDNEY TRANSPLANT	NHS ENGLAND	ANTINEOPLASTIC DRUGS	NOT ROUTINELY COMMISSIONED NHS ENGLAND CLINICAL COMMISSIONING POLICY: A07/P/c	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BORTEZOMIB	CANCER	NHS ENGLAND/ CDF	ANTINEOPLASTIC DRUGS	TA129, TA228, TA311, TA 378 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
BOSENTAN	DIGITAL ULCERS	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A13/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
BOSENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY		√		
BOSUTINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 401	NICE	NICE	SACT			√	
BOTULINUM TOXIN	FOCAL SPASTICITY IN CHILDREN	NHS ENGLAND	TORSION DYSTONIAS AND OTHER INVOLUNTARY MOVEMENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	AS PER POLICY		√		
BOTULINUM TOXIN****	INTRAVESICAL USE IN SPINAL CORD INJURY	NHS ENGLAND	TORSION DYSTONIAS AND OTHER INVOLUNTARY MOVEMENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	AS PER POLICY		√		
BRINCIDOFIVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
BRODALIMUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
C1 ESTERASE INHIBITORS	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
C1 ESTERASE INHIBITORS	HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 18045/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	√	√		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
CANAKINUMAB	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME	NHS ENGLAND	IMMUNOMODULATING DRUGS	CRYOPYRIN ASSOCIATED PERIODIC SYNDROME SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
CANAKINUMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED (TA302)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CARGLUMIC ACID	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
CARNITINE	CARNITINE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE				√
CASPOFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			√	
CATRIDEACOG	CONGENITAL FACTOR XIII A-SUBUNIT DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CERALIFIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CERLIPONASE ALFA	NEURONAL CEROID LIPOFUOSINOSIS	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CERTOLIZUMAB PEGOL	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CETUXIMAB	CANCER	NHS ENGLAND/ CDF	ANTINEOPLASTIC DRUGS	TA145, TA176 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
CHENODEOXYCHOLIC ACID	CEREBROTENDINOUS XANTHOMATOSIS (CTX)	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CHENODEOXYCHOLIC ACID	PRIMARY BILIARY CIRRHOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CHOLIC ACID	INBORN ERRORS IN PRIMARY BILE ACID SYNTHESIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CIDOFOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			√	
CIPROFLOXACIN INHALATION	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CIPROFLOXACIN LIPOSOMAL (INHALED)	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
CLADRIBINE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√****	
CLADRIBINE	PULMONARY LANGERHANS HISTIOCYTOSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
COBICISTAT	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03/P/a/AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
COBITOLIMOD	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
CO-CARELDOPA INTESTINAL GEL	PARKINSON'S DISEASE	NHS ENGLAND	NEURODEGENERATIVE CONDITIONS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: D04/P/e	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
COLISTIMETHATE SODIUM	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b TA276	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT			√*	√*
CONESTAT ALFA	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
CRIZOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NICE TA 406, 422	NICE	NICE	SACT			√	
CYSTEAMINE (MERCAPTAMINE)	NEPHROPATHIC CYSTINOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
DABRAFINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA321, 396	NICE	NICE	SACT	√ (TA396)	√		
DACLATASIVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 364	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	√	√		
DACLIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DARUNAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
DARUNAVIR + COBICISTAT (REZOLSTA®)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
DASABUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DASATINIB	CANCER	NHS ENGLAND/ CDF	PROTEIN KINASE INHIBITORS	NICE TA 425, 426 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
DECITABINE	CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED (TA270)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT		√		
DEFERASIROX	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/NATIONAL HAEMOGLOBINOPATHY REGISTRY		√		
DEFERIPRONE**	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/NATIONAL HAEMOGLOBINOPATHY REGISTRY		√		
DEFIBROTIDE	HEPATIC VENO-OCCLUSIVE DISEASE	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B04/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
DELAMANID	EXTENSIVELY DRUG RESITANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
DELAMANID	MULTI DRUG RESITANT TB	NHS ENGLAND	ANTITUBERCULOSIS DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F04/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
DESFERRIOXAMINE**	IRON CHELATION IN THALASSAEMIA AND SICKLE CELL	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMLYTIC, AND RENAL ANAEMIAS - IRON OVERLOAD	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16070/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	QUALITY DASHBOARD/NATIONAL HAEMOGLOBINOPATHY REGISTRY		√		
DEXRAZOXANE	ANTHRACYCLINE EXTRAVASATION	NHS ENGLAND	IMMUNOMODULATING DRUGS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				√	
DEXRAZOXANE	ANTHRACYCLINE CARDIOTOXICITY	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DIBOTERMIN ALFA	COMPLEX SPINAL SURGERY	NHS ENGLAND	BONE MORPHOGENETIC PROTEIN	NHS ENGLAND CLINICAL COMMISSIONING POLICY 16063/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AUDIT, BSR REGISTRY		√		
DIDANOSINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
DIMETHYL FUMARATE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA320	NICE	NICE	NICE AUDIT	√		√****	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
DOLUTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B06/P/b/AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
DORAVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DORNASE ALFA	PRIMARY CILIARY DYSKINESIA	NHS ENGLAND	MUCOLYTICS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16029/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DORNASE ALFA	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			√*	√*
DRISAPERSEN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
DUPILUMAB	ASTHMA	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ECALLANTIDE	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ECULIZUMAB	ORGAN REJECTION POST KIDNEY TRANSPLANT	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: A07/P/b	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ECULIZUMAB	C3 GLOMERULOPATHY (POST TRANSPLANT)	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16054/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ECULIZUMAB	AHUS	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/PS(HSS)/A NICE HST1	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE		√		
ECULIZUMAB	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS ENGLAND	PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA	NHS NATIONAL SPECIALISED COMMISSIONING TEAM SERVICE SPECIFICATION	NSCT SERVICE SPEC	NSCT SERVICE SPEC	NSCT SERVICE SPEC		√		
EDRATIDE	SLE	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EFAVIRENZ	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
EFRALECTOCOG ALFA / EFMORCOTOCOG ALFA / FACTOR VIII FC FUSION PROTEIN (Eloctaf®)	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK		√		
EFTRENONACOG ALFA (Alprolix®)	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	SSC 1652	SSC 1652	SSC 1652	PRODUCTS ON CMU FRAMEWORK		√		
ELBASVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 413	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS		√		
ELOGLUSTAT	GAUCHER'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ELOSULFASE ALFA	MUCOPOLYSACCHARIDOSIS IV TYPE A	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NICE HST2	MANAGED ACCESS AGREEMENT	MANAGED ACCESS AGREEMENT	MANAGED ACCESS AGREEMENT	√	√		
ELTROMBOPAG	ITP IN CHILDREN	NHS ENGLAND	PLATELET DISORDER DRUGS	AS PER ADULT TA 293	NICE	NICE	NICE AUDIT		√		
ELVITEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
ELVICITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
EMRICASAN	NON-ALCOHOLIC STEATOHEPATITIS (NASH) FIBROSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EMTRICITABINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
EMTRICITABINE + TENOFOVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
EMTRICITABINE + TENOFOVIR ALAFENAMIDE DESCOVY®	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
EMTRICITABINE + RILPIVIRINE + TENOFOVIR ALAFENAMIDE (JODEFSEY®)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
ENFUVRITIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
ENTECAVIR	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA153 & IN PROGRESS	NICE	NICE	NICE AUDIT			√	
ENZALUTAMIDE	CANCER	NHS ENGLAND	HORMONE ANTAGONISTS	TA316, TA 377 (SEE ALSO SSC1439) BOTH: ONLY IN ABIRATERONE NAIVE PATIENTS	NICE/NHS ENGLAND POLICY	NICE	SACT			√	
EPOPROSTENOL (5)	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
EPRATUZUMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EPRODISATE	AMYLOIDOSIS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EPTOTERMIN ALFA	COMPLEX SPINAL SURGERY	NHS ENGLAND	BONE MORPHOGENETIC PROTEIN	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ERLOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA162, TA227, TA 374 & IN PROGRESS NHSE LETTER	NICE	NICE	SACT			√	
ETANERCEPT	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√		√	
ETANERCEPT	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA103, TA130, TA143, TA199)	NICE	NICE	NICE AUDIT			√	
ETEPLIRSEN	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ETRAVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
ETROLIZUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EVEROLIMUS (AFINITOR®)	CANCER	NHS ENGLAND/ CDF	PROTEIN KINASE INHIBITORS	TA421 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
EVEROLIMUS (CERTICAN®)	PREVENTING ORGAN REJECTION IN LIVER TRANSPLANTATION	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED (TA348)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
EVEROLIMUS (CERTICAN®)	PREVENTING ORGAN REJECTION IN HEART TRANSPLANTATION	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16016/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
EVEROLIMUS (VOTUBIA®)	SUBEPENDYMAL GIANT CELL ASTROCYTOMA (SEGA) ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16066/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓	✓		
EVEROLIMUS (VOTUBIA®)	RENAL ANGIOMYOLIPOMA ASSOCIATED WITH TUBULAR SCLEROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY STATEMENT B14X09L	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓	✓		
EVOLOCUMAB	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	AS NICE TA 394 (FOLLOW GUIDANCE FOR HETEROZYGOUS FH)	NICE	NICE	NICE AUDIT		✓		
EX-VIVO EXPANDED AUTOLOGOUS HUMAN CORNEAL EPITHELIAL CELLS CONTAINING STEM CELLS	TREATMENT OF ADULT PATIENTS WITH MODERATE TO SEVERE LIMBAL STEM CELL DEFICIENCY (LSCD), UNILATERAL OR BILATERAL, DUE TO PHYSICAL OR CHEMICAL OCULAR BURNS	NHS ENGLAND		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
FACTOR IX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
FACTOR VII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				✓	
FACTOR VIIA	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
FACTOR VIII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
FACTOR VIII INHIBITOR BYPASSING FACTOR (FEIBA)	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
FACTOR XIII	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
FAMPRIDINE	MULTIPLE SCLEROSIS	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16010/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			✓****	
FIBRINOGEN	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				✓	
FIBROBLAST GROWTH FACTOR 1 GENE THERAPY	SOMATOSTATIN ANALOGUE	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
FILGOTINIB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			✓	
FILGRASTIM	BARTH SYNDROME	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			✓		
FILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	SPC	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED			✓	
FILIBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
FINGOLIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA254 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	✓		✓****	
FITUSIRAN	HAEMOPHILIA A AND B	NHS ENGLAND	ANAEMIAS AND SOME OTHER BLOOD DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
FLEBOGAMMA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
FLEBOGAMMADIF	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
FORIGERIMOD ACETATE	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
FOSAMPRENAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
FOSCARNET	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			✓	
FOSTEMSAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
GALSULFASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
GAMMAGARD	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
GAMMANORM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
GAMMAPLEX	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
GAMUNEX	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
GANCICLOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			✓	
GANETESPIB	CANCER	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	SACT			✓	
GEFITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA192	NICE	NICE	SACT			✓	
GEVOKIZUMAB	UVEITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
GLATIRAMER	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA32 & NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	✓		✓****	
GLECAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
GLUCARPIDASE	METHOTREXATE INDUCED RENAL DYSFUNCTION	NHS ENGLAND	POISONING	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B15/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
GLYCEROL PHENYL BUTYRATE	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
GLYCOPEGYLATED FACTOR IX GOLIMUMAB	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULTS TAs (TA220, TA233)	NICE	NICE	NICE AUDIT			✓	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (LEUKINE® - IMPORT)	ANTIBODY-POSITIVE PULMONARY ALVEOLAR PROTEINOSIS	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
GRAZOPREVRIL	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 413	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	√	√		
HIV VACCINE	HIV INFECTION PROPHYLAXIS	NHS ENGLAND	VACCINES AND ANTISERA	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
HIZENTRA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
HUMAN (HAEM) ARGINATE	HEPATIC PORPHYRIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
HUMAN HETEROLOGOUS LIVER CELLS	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
HUMAN PARATHYROID HORMONE-RELATED PROTEIN ANALOGUE	MALE AND JUVENILE OSTEOPOROSIS HYPOPARATHYROIDISM	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
HYQVIA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
IBALIZUMAB	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ICATIBANT	HEREDITARY ANGIOEDEMA - ACUTE TREATMENT ONLY	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B09/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
ICATIBANT	HEREDITARY ANGIOEDEMA - PROPHYLACTIC TREATMENT	NHS ENGLAND	ALLERGIC EMERGENCIES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16045/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY	√	√		
IDEBENONE	DUCHENNE MUSCULAR DYSTROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
IDURSULFASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
ILOPROST (5)	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
IMATINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA70, TA86, TA251, TA326	NICE	NICE	SACT			√	
IMATINIB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
IMGLUCERASE	GAUCHER'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
INDINAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
INFLIXIMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√	√		
INFLIXIMAB	UVEITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: D12/P/a & D12/P/a)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
INFLIXIMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA130, TA134, TA140, TA143, TA163, TA199)	NICE	NICE	NICE AUDIT			√	
INFLIXIMAB	CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
INFLIXIMAB	CRONH'S DISEASE IN CHILDREN	NHS ENGLAND	CYTOKINE MODULATORS	TA187	NICE	NICE	NICE AUDIT			√	
INFLIXIMAB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√			
INFLIXIMAB	RENAL	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√			
INFLIXIMAB	SARCOIDOSIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	√			
INFLIXIMAB	HIDRADENITIS SUPPURATIVA	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - NHS ENGLAND POLICY 16018/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
INFLIXIMAB	BEHCETS SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA		√		
INTERFERON ALFA	HEPATITIS B AND C	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA75	NICE	NICE	NICE AUDIT			√	
INTERFERON BETA	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA32	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER NHSE POLICY	√		√****	
INTRATECT	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
ISAVUCONAZOLE	FUNGAL INFECTION (LICENSED INDICATIONS)	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			√	
IVACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/c, 16049/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√		
IXAZOMIB	AMYLOIDOSIS/ MULTIPLE MYELOMA	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
KIOVIG	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
LAMIVUDINE	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	CG165	NICE	NICE	NICE AUDIT			√	
LAMIVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
LANREOTIDE	CANCER	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED				√
LANREOTIDE	CONGENITAL HYPERINSULINISM	NHS ENGLAND	SOMATOSTATIN ANALOGUES	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			√		
LANREOTIDE***	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED		√		√
LAPATINIB	CANCER	CDF	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	CDIFR	CDIFR	SACT			√	
LAQUINIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√****	
LARONADASE	MUCOPOLYSACCHARIDOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
LEBRKIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
LENALIDOMIDE	CANCER	NHS ENGLAND/ CDF	IMMUNOMODULATING DRUGS	TA171, TA322 CDF POLICY	NICE CDF	NICE CDF	SACT			√	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
LENOGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	SPC	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY PRODUCT WITH LOWEST ACQUISITION COST TO BE USED			✓	
LENOGRASTIM	BARTH SYNDROME	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			✓		
LETERMOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LEVOFLOXACIN (INHALED)	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LIPEFILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LIXVAPTAN	HYPONATRAEMIA AND OTHER ENDOCRINE USES	NHS ENGLAND	POSTERIOR PITUITARY HORMONES AND ANTAGONISTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LOMITAPIDE	HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA	NHS ENGLAND	LIPID-REGULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LONAFARNIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
LOPINAVIR + RITONAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	AGREED REGIONAL GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
LUMACAFTOR AND IVACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NOT ROUTINELY COMMISSIONED TA IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MACIMORELIN	GROWTH FAILURE	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MACITENTAN	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MANNITOL	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b TA266	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT			✓	
MARAVIROC	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
MASITINIB	PANCREATIC CANCER/GIST	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MAVRILMUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓	✓	
MECASERMIN	GROWTH FAILURE	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY		✓		
MEPOLIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED TA IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
METRELLEPTIN	DYSLIPIDAEMIA	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MICAFUNGIN	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			✓	
MIGALASTAT	FABRY'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
MIGLUSTAT	GAUCHER'S DISEASE/ NIEMANN-PICK	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
MOMELOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
MOTAVIZUMAB	RSV PROPHYLAXIS	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓	✓	
NATALIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA127 NHS ENGLAND POLICY: D04/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	✓		✓****	
NELFINAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET		✓	
NEVIRAPINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET		✓	
NILOTINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA241, TA251	NICE	NICE	SACT			✓	
NINTEDANIB	OVARIAN CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	CDIFR	CDIFR	SACT		✓		
NINTEDANIB (OFEV®)	IDIOPATHIC PULMONARY FIBROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA 379	NICE	NICE	NICE AUDIT	✓	✓		
NINTEDANIB (VARGATEF®)	NON-SMALL-CELL LUNG CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA347	NICE	NICE	SACT			✓	
NITAZOXANIDE	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
NITISINONE	ALKAPTONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
NITISINONE	TYROSINAEMIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
NITRIC OXIDE	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				✓	
NONACOG ALPHA (BeneFIX)	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				✓	
NONACOG BETA PEGOL	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
NORMAL IMMUNOGLOBULIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
OBETICHOIC ACID	PRIMARY BILIARY CIRRHOSIS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
OCRELIZUMAB	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
OCTAGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
OCTOCOG ALFA	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
OCTREOLIN	ACROMEGALY	NHS ENGLAND	GROWTH HORMONE & GROWTH HORMONE RECEPTOR ANTAGONIST	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
OCTREOTIDE	CANCER	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED				✓
OCTREOTIDE	CONGENITAL HYPERINSULINISM	NHS ENGLAND	SOMATOSTATIN ANALOGUES	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			✓		
OCTREOTIDE***	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED				✓

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
OFATUMUMAB	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA344	NICE	NICE	SACT			✓	
OFATUMUMAB	PEMPHIGUS VULGARIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	✓			
OLESOXIME	SPINAL MUSCULAR ATROPHY	NHS ENGLAND	NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	✓			
OMALIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	TA278	NICE	NICE	NICE AUDIT	✓		✓	
OMBITASVIR/PARITAPREVIR/RITONAVIR + DASABUVIR + RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 365	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	✓	✓		
OSILODROSTAT	CUSHING'S DISEASE	NHS ENGLAND	OTHER ENDOCRINE DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	✓			
OZANIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	✓			
PACRITINIB	MYELOFIBROSIS	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL	✓			
PALIVIZUMAB	RSV PROPHYLAXIS	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	JCVI GUIDELINES	AS PER SPECIFICATION	AS PER SPECIFICATION		✓		✓	
PARA-AMINOSALICYLIC ACID	TB	NHS ENGLAND	ANTI-TUBERCULOSIS DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PARATHYROID HORMONE	SPECIALIST ENDOCRINOLOGY CONDITIONS	NHS ENGLAND	PARATHYROID HORMONE	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				✓	
PARENTERAL NUTRITION (HOME USE)	INTESTINAL FAILURE	NHS ENGLAND	PARENTERAL NUTRITION	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AS PER BLUETEQ FORM	AUDIT	✓	✓		
PARENTERAL NUTRITION (INPATIENT USE)	INTESTINAL FAILURE: INADEQUATE/ UNSAFE ENTERAL FEEDING	NHS ENGLAND	PARENTERAL NUTRITION	ONLY WHEN DURATION OF PN IS > 14 DAYS OR INITIATED PRIOR TO ADMISSION. ADULTS; SEE ALSO CG32. SEE ALSO MANUAL FOR PRESCRIBED SPECIALISED SERVICES	TRUST GUIDELINES	TRUST GUIDELINES				✓	
PARITAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PASIREOTIDE	ACROMEGALY	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16903/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PASIREOTIDE	CUSHING'S DISEASE	NHS ENGLAND	SOMATOSTATIN ANALOGUES	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16052/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
PAZOPANIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA215	NICE	NICE	SACT			✓	
PEG INTERFERON ALFA	HEPATITIS B AND C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B07/P/a; TA75, TA96, TA106, TA200, TA 300 CG165	NICE	NICE	NICE AUDIT			✓	
PEGFILGRASTIM	NEUTROPENIA	NHS ENGLAND	DRUGS USED IN NEUTROPENIA	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PEGINTERFERON BETA-1A	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	ROUTINELY COMMISSIONED AS PER SSC1534: MULTIPLE SCLEROSIS FIRST LINE DISEASE MODIFYING AGENTS	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NICE AUDIT	✓		✓****	
PEGINTERFERON LAMBDA-1A	HEPATITIS C	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PEGVISOMANT	ACROMEGALY	NHS ENGLAND	HYPOTHALMIC & ANTERIOR PITUITARY HORMONES & ANTI-GESTROGENS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16050/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
PEMBROLIZUMAB	MELANOMA (UNRESECTABLE, METASTATIC)	NHS ENGLAND	CANCER EXCLUSION	TA 357	NICE	NICE	SACT			✓	
PEMBROLIZUMAB	TREATMENT NAIVE MELANOMA (UNRESECTABLE, METASTATIC)	NHS ENGLAND	CANCER EXCLUSION	TA 366	NICE	NICE	SACT			✓	
PIRFENIDONE	IDIOPATHIC PULMONARY FIBROSIS	NHS ENGLAND	PULMONARY FIBROSIS	TA282 (SPECIALIST CENTRE ONLY)	NICE	NICE	NICE AUDIT	✓	✓		
PLERIXAFOR	STEM CELL MOBILISATION	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B04/P/b, 16064/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NUMBER OF PATIENTS TREATED NUMBER OF PATIENTS SUCCESSFULLY TRANSPLANTED STAGE DRUG UTILISED	✓	✓		
POMALIDOMIDE	CANCER	CDF	IMMUNOMODULATING DRUGS	CDF POLICY	CDF	CDF	SACT			✓	
POMALIDOMIDE	MYELOFIBROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PONATINIB	CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT			✓	
PONESIMOD	MULTIPLE SCLEROSIS	NHS ENGLAND	DRUGS USED FOR NEUROMUSCULAR DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PORACTANT ALFA	RESPIRATORY DISTRESS SYNDROME	NHS ENGLAND	PULMONARY SURFACTANTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED		✓		
POSACONAZOLE	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY			✓	
PRETOMANID	MULTI DRUG RESISTANT TB	NHS ENGLAND	ANTI-TUBERCULOSIS DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
PRIVIGEN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
PROTEIN C	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
PROTHROMBIN COMPLEX	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES	PRODUCTS ON CMU FRAMEWORK			✓	
RALTEGRAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
RASBURICASE	HYPERURICAEMIA	NHS ENGLAND	GOUT AND CYTOTOXIC-INDUCED HYPERURICAEMIA	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES				✓	
REGORAFENIB	CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT			✓	
RESLIZUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
REVEGLUCOSIDASE ALFA	POMPE DISEASE	NHS ENGLAND	LYSOSOMAL STORAGE DISORDER DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: B07/P/a; TA75, TA106, TA200	NICE	NICE	NICE AUDIT PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			✓	
RIGOSERTIB	MDS/PANCREATIC CANCER	NHS ENGLAND	MYELODYSPLASTIC SYNDROME	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RILONACEPT	CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES	NHS ENGLAND	IMMUNOMODULATING DRUGS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RILPIVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
RIOCIGUAT	PULMONARY ARTERIAL HYPERTENSION (CTEPH)	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RIOCIGUAT	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16055/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
RITONAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
RITUXIMAB	STEROID SENSITIVE NEPHROTIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/b	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RITUXIMAB	STEROID RESISTANT NEPHROTIC SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RITUXIMAB	PRIMARY SJOGREN'S SYNDROME (PSS)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RITUXIMAB	CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RITUXIMAB	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓		✓	
RITUXIMAB	ACQUIRED HAEMOPHILIA	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F02/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RITUXIMAB	ANCA-POSITIVE VASCULITIS	NHS ENGLAND	CYTOKINE MODULATORS	TA308 NHS ENGLAND POLICY: A13/P/a	NICE/ NHS ENGLAND POLICY	NICE/ NHS ENGLAND POLICY	NICE/ NHS ENGLAND POLICY			✓	
RITUXIMAB	CONNECTIVE TISSUE DISEASE - INTERSTITIAL LUNG DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED - POLICY IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RITUXIMAB	CYTOPENIA COMPLICATING PRIMARY IMMUNODEFICIENCY	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16044/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RITUXIMAB	GRAFT VERSUS HOST DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RITUXIMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A13/PS/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			✓	
RITUXIMAB	MYOSITIS	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16035/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			✓	
RITUXIMAB	NEPHRITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RITUXIMAB	NEURORHEUMATISM OPTICA	NHS ENGLAND	CYTOKINE MODULATORS	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION		✓		
RITUXIMAB	ABO-INCOMPATIBLE KIDNEY TRANSPLANTS	NHS ENGLAND	CYTOKINE MODULATORS	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION	AS PER SPECIFICATION		✓		
RITUXIMAB	PEMPHIGUS VULGARIS AND PEMPHIGOID DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16035/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY			✓	
RITUXIMAB	IMMUNOGLOBULIN G4 RELATED DISEASE	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16057/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		✓		
RITUXIMAB IV	CANCER	NHS ENGLAND	CYTOKINE MODULATORS	TA65, TA137, TA174, TA193, TA226, TA243 NHS ENGLAND CDF LETTER	TA65, TA137, TA174, TA193, TA226, TA243 NHS ENGLAND CDF LETTER	TA65, TA137, TA174, TA193, TA226, TA243 NHS ENGLAND CDF LETTER	SACT			✓	
RITUXIMAB SUBCUTANEOUS FORMULATION	CANCER	NHS ENGLAND	CYTOKINE MODULATORS	AS PER CIRCULAR IE ONLY COMMISSIONED FOR FOLLICULAR LYMPHOMA MAINTENANCE TREATMENT	AS PER CIRCULAR	AS PER CIRCULAR	SACT			✓	
ROPEGINTERFERON ALFA-2b	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
ROXADUSTAT	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
RUXOLITINIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA 386	NICE	NICE	SACT			✓	
SANDOGLOBULIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			✓	
SAPROPTERIN	CHILDREN WITH PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED (NHS ENGLAND CLINICAL COMMISSIONING POLICY: E06/P/a)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SAPROPTERIN	MATERNAL PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E12/P/a	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HIGHLY SPECIALISED DATABASE		✓		
SAQUINAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			✓	
SARILUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			✓	
SEBELIPISE ALFA	LYSOSOMAL ACID LIPASE DEFICIENCY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED NICE HST IN PROGRESS	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SECUKINUMAB	PAEDIATRIC INDICATIONS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SELEXIPAG	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 160017/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SETROBUVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SIALIC ACID	MYOPATHY	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SILDENAFIL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			✓	
SIMEPREVIR/PEGINTERFERON + RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 331	NICE	NICE	HEPATITIS C MDS	✓	✓		
SIRUKUMAB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	DRUGS AFFECTING THE IMMUNE RESPONSE	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			✓	
SODIUM BENZOATE	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		✓		
SODIUM OXYBATE	NARCOLEPSY - PAEDIATRIC SERVICES ONLY	NHS ENGLAND	HYPNOTICS & ANXIOLYTICS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16065/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	✓	✓		
SODIUM PHENYLBUTYRATE	UREA CYCLE DISORDERS	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		✓		
SOFOSBUVIR/DACLATASVIR + RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 364	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	✓	✓		
SOFOSBUVIR/LEDIPASVIR +/- RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 363	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	✓	✓		
SOFOSBUVIR/PEGINTERFERON+ RIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA 330	AS PER RUN RATE CARD	AS PER RUN RATE CARD	HEPATITIS C MDS	✓	✓		
SORAFENIB	CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT			✓	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
STAVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
SUBCUIVIA	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
SUBGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
SUNITINIB	CANCER	NHS ENGLAND/ CDF	PROTEIN KINASE INHIBITORS	TA169, TA179 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
SUSOCTOCOG ALFA (OBIZUR)	HAEMOPHILIA A	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TABALUMAB	SLE	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TADALAFIL	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	NHS ENGLAND POLICY	NHS ENGLAND POLICY	AS PER POLICY			√	
TALIGLUCERASE ALFA	GAUCHER'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
TARIBAVIRIN	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TEDUGLUTIDE	SHORT BOWEL SYNDROME	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TELAPREVIR	HEPATITIS C	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	TA252	NICE	NICE	HEPATITIS C MDS	√		√	
TELBIVUDINE	HEPATITIS B	NHS ENGLAND	VIRAL HEPATITIS (B&C) & RESPIRATORY SYNCYTIAL VIRUS	NOT ROUTINELY COMMISSIONED (TA154)	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TEMSIROLIMUS	CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT			√	
TENOFOVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS HEPATITIS B +/ OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	TA173 (FOR HEPATITIS B)/AGREED REGIONAL GUIDELINES FOR HIV	BHIVA GUIDELINES (8) NICE	BHIVA GUIDELINES (8) NICE	HARS DATASET			√	
TENOFOVIR ALAFENAMIDE	HEPATITIS B	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
TENOFOVIR ALAFENAMIDE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
TENOFOVIR ALAFENAMIDE + COBICISTAT + ELVITEGRAVIR + EMTRICITABINE (GENVOYA™)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: 16043/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
TENOFOVIR DISOPROXIL + COBICISTAT + ELVITEGRAVIR + EMTRICITABINE (STRIBILD™)	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: F03P/b/AGREED REGIONAL GUIDELINES	NHS ENGLAND POLICY	NHS ENGLAND POLICY	HARS DATASET			√	
TENOFOVIR + EMTRICITABINE + EFAVIRENZ	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
TENOFOVIR + EMTRICITABINE + RILPIVIRINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
TERIFLUNOMIDE	MULTIPLE SCLEROSIS	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA303 NHS ENGLAND POLICY: D04/P/b	NICE	NICE	NICE AUDIT	√		√****	
TERIPARATIDE	OSTEOGENESIS IMPERFECTA	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY: 16002/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TERIPARATIDE	MALE AND JUVENILE OSTEOPOROSIS	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TETRAHYDROBIOPTERIN	PHENYLKETONURIA	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
TEZACAFTOR	CYSTIC FIBROSIS	NHS ENGLAND	MUCOLYTICS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
THALIDOMIDE	CANCER	NHS ENGLAND	IMMUNOMODULATING DRUGS	TA228	NICE	NICE	SACT			√	
THROMBIN	PSEUDOANEURYSM	NHS ENGLAND	BLOOD-RELATED PRODUCTS	IPG060	IPG060	NICE				√	
TIPRANAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
TOBRAMYCIN	CYSTIC FIBROSIS	NHS ENGLAND	ANTIBACTERIAL DRUGS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: A01/P/b TA276	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE	NHS ENGLAND POLICY NICE AUDIT			√*	√*
TOCILIZUMAB IV	JUVENILE ARTHRITIS-PAEDIATRIC	NHS ENGLAND	CYTOKINE MODULATORS	NHS ENGLAND CLINICAL COMMISSIONING POLICY: E03/P/d, TA 373	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY	√		√	
TOCILIZUMAB IV	TAKAYASU ARTERITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16056/P	NHS ENGLAND POLICY	NHS ENGLAND POLICY	NHS ENGLAND POLICY		√		
TOCILIZUMAB IV	GIANT CELL ARTERITIS	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED NHS ENGLAND POLICY 16019/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TOCILIZUMAB IV	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TA'S (TA247 and TA375)	NICE	NICE	NICE AUDIT			√	
TOFACITINIB	PAEDIATRIC INDICATIONS (WHERE ADULT TA AVAILABLE)	NHS ENGLAND	CYTOKINE MODULATORS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
TOLVAPTAN	HYPONATRAEMIA IN CANCER	NHS ENGLAND	POSTERIOR PITUITARY HORMONES AND ANTAGONISTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TRALKINUMAB	ASTHMA	NHS ENGLAND	ALLERGEN IMMUNOTHERAPY	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TRENONACOG ALPHA	HAEMOPHILIA B	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TREPROSTINIL DIETHANOLAMINE	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TREPROSTINIL SODIUM	PULMONARY ARTERIAL HYPERTENSION	NHS ENGLAND	VASODILATOR ANTIHYPERTENSIVE DRUGS/PULMONARY ARTERIAL HYPERTENSION	NOT ROUTINELY COMMISSIONED FOR NEW PATIENTS - NHS ENGLAND CLINICAL COMMISSIONING POLICY: A11/P/c	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
TRIENTENE	WILSON'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
TUROCTOCOG ALFA (NovoEight)	AS PER BCSH GUIDELINES FOR SPECIALISED INDICATIONS	NHS ENGLAND	BLOOD-RELATED PRODUCTS	BCSH GUIDELINES	BCSH GUIDELINES	BCSH GUIDELINES				√	
USTEKINUMAB	PAEDIATRIC INDICATIONS	NHS ENGLAND	DRUGS AFFECTING IMMUNE RESPONSE	AS PER ADULT TA180	NICE	NICE	NICE			√	
VADADUSTAT	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	DRUGS USED IN HYPOPLASTIC, HAEMOLYTIC, AND RENAL ANAEMIAS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
VALGANCICLOVIR	CYTOMEGALOVIRUS	NHS ENGLAND	CYTOMEGALOVIRUS INFECTION	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY				√
VANDETANIB	THYROID CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT CDF NATIONAL AUDIT		√		
VEZOLIZUMAB	IBD IN CHILDREN	NHS ENGLAND	CYTOKINE MODULATORS	AS PER ADULT TAs - TA 342, TA 352	NICE	NICE	NICE AUDIT		√		
VELAGLUCERASE ALFA	GAUCHER'S DISEASE	NHS ENGLAND	DRUGS USED IN METABOLIC DISORDERS	NHS ENGLAND SERVICE SPECIFICATION	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED DATABASE		√		
VELCALCETIDE	HYPERPARATHYROIDISM	NHS ENGLAND	DRUGS AFFECTING BONE METABOLISM	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
VEMURAFENIB	MELANOMA	NHS ENGLAND	PROTEIN KINASE INHIBITORS	TA269	NICE	NICE	NICE AUDIT		√		
VIGAM	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
VIVAGLOBIN	AS PER NATIONAL DMP	NHS ENGLAND	INTRAVENOUS/SUBCUTANEOUS HUMAN NORMAL IMMUNOGLOBULINS	CLINICAL GUIDELINES FOR IMMUNOGLOBULIN USE, SECOND EDITION UPDATE (JULY 2011)	NATIONAL GUIDELINES	NATIONAL GUIDELINES	QUALITY DASHBOARD			√	
VON WILLEBRAND FACTOR, RECOMBINANT	VON WILLEBRAND DEFICIENCY	NHS ENGLAND	BLOOD-RELATED PRODUCTS	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
VORICONAZOLE	FUNGAL INFECTION	NHS ENGLAND	ANTIFUNGALS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES	NUMBER OF PATIENTS TREATED PROPORTION GIVEN FOR SPC INDICATIONS WITHIN POLICY				√
VORICONAZOLE	CHRONIC PULMONARY ASPERGILLOSIS	NHS ENGLAND	ANTIFUNGALS	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY	HIGHLY SPECIALISED CRITERIA ONLY			√		
ZICONOTIDE	INTRATHECAL ANALGESIA	NHS ENGLAND	NON-OPIOID ANALGESICS	NOT ROUTINELY COMMISSIONED - NHS ENGLAND POLICY 16011/P	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
ZIDOVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
ZIDOVUDINE + LAMIVUDINE	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
ZIDOVUDINE + LAMIVUDINE + ABACAVIR	HIV IN COMBINATION WITH OTHER ANTI-RETROVIRAL DRUGS	NHS ENGLAND	AIDS/HIV ANTIRETROVIRALS	AGREED REGIONAL GUIDELINES	BHIVA GUIDELINES (8)	BHIVA GUIDELINES (8)	HARS DATASET			√	
OTHER DRUGS NOT LISTED UNDER PBR EXCLUSIONS											
3,4 DIAMINOPYRIDINE	LAMBERT EATON MYASTHENIC SYNDROME	NHS ENGLAND		AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES			√		
AFLIBERCEPT	CANCER	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER CDIFR APPROVAL	AS PER CDIFR APPROVAL	SACT			√	
ALBUMIN BOUND PACLITAXEL	TREATMENT OF BREAST CANCER PATIENTS WITH DOCUMENTED TAXANE HYPERSENSITIVITY	NHS ENGLAND	CANCER EXCLUSION	NHS ENGLAND ROUTINELY COMMISSIONED LETTER	NHS ENGLAND ROUTINELY COMMISSIONED LETTER	NHS ENGLAND ROUTINELY COMMISSIONED LETTER	SACT			√	
AZATHIOPRINE	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES				√*	√*
BENDAMUSTINE	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA216	NICE CDF	NICE CDF	SACT			√	
BRENTUXIMAB	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	
CABAZITAXEL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 391	NICE	NICE	SACT	√		√	
CABOZANTINIB	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	
CERITINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 395	NICE	NICE	SACT	√		√	
CHEMOTHERAPY	CANCER - (NOT SPECIFICALLY LISTED)	NHS ENGLAND/ CDF	CANCER EXCLUSION	TRUST GUIDELINES/ NICE/ CDF POLICY	TRUST GUIDELINES/ NICE/ CDF POLICY	TRUST GUIDELINES/ NICE/ CDF POLICY	SACT			√	
CICLOSPORIN	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*
CINACALCET	HYPERPARATHYROIDISM - DIALYSIS PATIENTS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TA117	NICE	NICE					√
CLOFARABINE	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	
COLESTILAN	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS	TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES					√
DARBEPOETIN	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	ERYTHROPOETINS	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√	
EPOETIN (ALL VARIANTS)	DIALYSIS-INDUCED ANAEMIA	NHS ENGLAND	ERYTHROPOETINS	RENAL DIALYSIS ONLY, INCLUDING VIA OUTPATIENTS, AND ONLY AS PER NICE CG114	NICE TRUST GUIDELINES (RENAL USE ONLY)	NICE TRUST GUIDELINES (RENAL USE ONLY)	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED (NICE CG114)			√	
ERIBULIN	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	NICE TA 423	NICE CDF	NICE CDF	SACT			√	
IBRUTINIB	CANCER	CDF	PROTEIN KINASE INHIBITORS	CDF POLICY	CDF	CDF	SACT			√	
DELALISIB	CANCER	NHS ENGLAND	PROTEIN KINASE INHIBITORS	NICE TA 359	NICE	NICE	SACT			√	
IPILIMUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA288, TA319, 400	NICE	NICE	SACT			√	
LANTHANUM	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS		TRUST GUIDELINES	TRUST GUIDELINES					√
MESENCHYMAL STEM CELLS (E.G. PROCHYMAL®)	ACUTE GVHD AND OTHER INDICATIONS (BCSH)	NHS ENGLAND		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
MYCOPHENOLATE MOFETIL	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*
MYCOPHENOLIC ACID	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*
NELARABINE	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	
NIVOLUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 384, 400, 417	NICE	NICE	SACT			√	
OBINUTUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA343	NICE	NICE	SACT			√	
OLAPARIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 381	NICE	NICE	SACT			√	
OSIMERTINIB	CANCER	CDF	CANCER EXCLUSION	TA 416	CDF	CDF	SACT			√	
PANITUMUMAB	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT		√		
PANOBINOSTAT	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 380	NICE	NICE	SACT		√		
PEGASPARGASE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 408	NICE	NICE	SACT		√		
PEGLATED EPSONORAL DECADEXAN	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA 401	NICE	NICE	SACT			√	
PEMETREXED	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	TA135, TA181, TA190, TA 402	NICE CDF	NICE CDF	SACT			√	

DRUG NAME	INDICATION	COMMISSIONER	PBR CATEGORY	TA/POLICY	STARTING CRITERIA	STOPPING CRITERIA	MONITORING/AUDIT REQUIREMENTS	PRIOR APPROVAL PROFORMA REQUIRED	SPECIALIST CENTRE ONLY (including outreach when delivered as part of a provider network)	SUITABLE FOR SHARED CARE BETWEEN SPECIALIST AND SECONDARY CARE VIA NETWORK MODEL	SUITABLE FOR SHARED CARE WITH PRIMARY CARE (IF SUPPORTED BY LOCAL PRESCRIBING COMMITTEE)
PEPTIDE RECEPTOR RADIONUCLIDE THERAPY	CANCER	CDF		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
PERTUZUMAB	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	NICE TA 424 CDF POLICY	NICE CDF	NICE CDF	SACT			√	
PIXANTRONE	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA306	NICE	NICE	SACT		√		
POMALIDOMIDE	CANCER	CDF	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
PROTEIN KINASE INHIBITORS	ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS	NHS ENGLAND		NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL		√		
RADIUM-223 DICHLORIDE	CANCER	NHS ENGLAND/ CDF	CANCER EXCLUSION	NICE TA 376, TA 412	NICE CDF	NICE CDF	SACT		√		
RAMUCIRUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED - TA 378	CDIFR	CDIFR	AS PER IFR APPROVAL		√		
SEVELAMER	ADULT RENAL DIALYSIS ONLY	NHS ENGLAND	DRUGS FOR MINERAL BONE DISORDERS		TRUST GUIDELINES	TRUST GUIDELINES					√
SIROLIMUS (RAPAMUNE)	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*
SUCROFERRIC OXYDROXIDE	CONTROL OF SERUM PHOSPHORUS LEVELS IN DIALYSIS PATIENTS	NHS ENGLAND	PHOSPHATE BINDING AGENTS	AGREED TRUST GUIDELINES	TRUST GUIDELINES	TRUST GUIDELINES					√
TACROLIMUS	TRANSPLANT IMMUNOSUPPRESSION ONLY	NHS ENGLAND		NEW PATIENTS ONLY UNTIL FORMAL REPATRIATION AGREED	TRUST GUIDELINES	TRUST GUIDELINES	PRODUCT WITH LOWEST PROCUREMENT COST TO BE USED			√*	√*
TALIMOGENE LAHERPAREPVEC	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 410	NICE	NICE	SACT		√		
TEMOZOLOMIDE	ENDOCRINOLOGY; NON-MALIGNANT CONDITIONS	NHS ENGLAND	CANCER EXCLUSION	NOT ROUTINELY COMMISSIONED	AS PER IFR APPROVAL	AS PER IFR APPROVAL	AS PER IFR APPROVAL			√	
TRABECTEDIN	CANCER	NHS ENGLAND	ANTINEOPLASTIC DRUGS	TA185	NICE	NICE	SACT			√	
TRAMETINIB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 396	NICE	NICE	SACT	√		√	
TRASTUZUMAB	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 34, 107, 208	NICE	NICE	SACT			√	
TRASTUZUMAB EMTANSINE	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	
TRIFLURIDINE-TIPIRACIL	CANCER	NHS ENGLAND	CANCER EXCLUSION	TA 405	NICE	NICE	SACT			√	
VISMODEGIB	CANCER	CDF	CANCER EXCLUSION	CDF POLICY	CDF	CDF	SACT			√	

* DRUG IS BEING REPATRIATED FROM PRIMARY TO SECONDARY CARE THEREFORE SUPPLY ROUTE MAY VARY AT PRESENT

** ROUTINELY COMMISSIONED IN COMBINATION WHEN DUAL THERAPY REQUIRED

*** ONLY WHEN PRESCRIBED IN A SPECIALIST CENTRE

**** ONLY WHERE IT IS A RECOGNISED MS CENTRE WITH SPECIALIST NURSE SUPPORT

NEW DRUGS ADDED TO 2017/2018
EXCLUSIONS' LIST
CHANGES TO 16/17 LIST

ADDITIONAL NOTES:

- WHERE THE FUNDED INDICATION IS FOR PAEDIATRIC USE THE CCG WILL BECOME THE RESPONSIBLE COMMISSIONER WHEN THE PATIENT IS TRANSFERRED TO THE ADULT SERVICE
- CCGS ARE THE RESPONSIBLE COMMISSIONER FOR RITUXIMAB IN NON CANCEROUS HAEMATOLOGICAL CONDITIONS (EG ITP) AND NON SPECIALIST AUTO-INFLAMMATORY CONDITIONS (EG RA)
- ELTROMBOPAG AND ROMIPLOSTIM ARE THE RESPONSIBILITY OF CCGS REGARDLESS OF THE CAUSE OF THE THROMBOCYTOPENIA IN ADULTS (PAEDIATRICS ARE NHS ENGLAND RESPONSIBILITY)
- IT IS A MANDATED REQUIREMENT THAT ALL USE OF CHEMOTHERAPY IS RECORDED IN THE SACT DATABASE INCLUDING THOSE TREATMENTS FUNDED THROUGH THE CDF
- USE IN VASCULAR DISEASE IS COMMISSIONED BY NHS ENGLAND WITHIN SPECIALIST CENTRES - ALL OTHER INDICATIONS ARE CCG COMMISSIONED
- NHS ENGLAND IS THE RESPONSIBLE COMMISSIONER WHEN SOMATROPIN ANALOGUES (GROWTH HORMONE) ARE PRESCRIBED IN SPECIALIST CENTRES FOR INDICATIONS FALLING OUTSIDE NICE GUIDANCE
- A DEROGATION LIST CAN BE FOUND UNDER EACH PROGRAMME OF CARE - PLEASE REFER TO THIS LINK - [HTTPS://WWW.ENGLAND.NHS.UK/COMMISSIONING/SPEC-SERVICES/NPC-CRG/](https://www.england.nhs.uk/commissioning/spec-services/npc-crg/)**
- NHS ENGLAND COMMISSIONS ARV5 AS PER PUBLISHED POLICIES, FOR THE TREATMENT OF PEOPLE WITH DIAGNOSED HIV INFECTION AND FOR THOSE THOUGHT TO BE HIV POSITIVE (POST EXPOSURE PROPHYLAXIS). NHS ENGLAND DOES NOT ROUTINELY COMMISSION PRE-EXPOSURE PROPHYLAXIS AND THIS IS ONLY AVAILABLE TO
- DRUGS APPROVED BY NICE FOR ADULT CONDITIONS WILL BE COMMISSIONED IN CHILDREN AT SPECIALISED PAEDIATRIC CENTRES IF THE PATIENT MEETS THE NICE CRITERIA AND THERE IS EVIDENCE TO SUGGEST THAT THE DRUG IS SAFE AND CLINICALLY APPROPRIATE TO USE IN CHILDREN. A PRESCRIBING POLICY IS IN DEVELOPMENT TO CLARIFY THESE ARRANGEMENTS. THIS WILL APPLY TO ANY DRUG WHERE WE HAVE STATED "AS PER ADULT TA" AS THE TA/ POLICY. A PRIOR APPROVAL SYSTEM WILL BE IMPLEMENTED ALONG SIDE THE POLICY.
- CINACALCET FOR COMPLEX PRIMARY PARATHYROIDISM IS IN TARIFF